Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02049905 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
A Phase 3 study, sponsored by ImmunityBio.
- Completed
- Registry status
- Phase 3
- Development phase
- 433
- Enrollment target
NCT02049905 is a Phase 3 study that has completed, run by ImmunityBio. The registered enrollment target is 433 participants.
The verdict
NCT02049905, a Phase 3 study, has completed, sponsored by ImmunityBio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 433 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of aldoxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas.
Interventions
- DRUG Aldoxorubicin
- DRUG Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 433 participants |
| Start Date | 2014-01 |
| Est. Completion | 2017-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02049905
The ClinicalTrials.gov registry entry for NCT02049905 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 433 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aldoxorubicin is the first listed.
NCT02049905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02049905 about?
NCT02049905 is a clinical study titled "Phase 3 Study to Treat Patients With Soft Tissue Sarcomas". The purpose of this study is to determine the efficacy and safety of aldoxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas.
What is the current status of trial NCT02049905?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 433 participants. The study started on 2014-01. Estimated completion is 2017-05.
What interventions are being tested in trial NCT02049905?
The interventions under investigation include: Aldoxorubicin (DRUG), Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide) (DRUG).
Who is sponsoring clinical trial NCT02049905?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.